Key Developments: Diagnos Inc (ADK.V)

ADK.V on TSX Venture Exchange

0.08CAD
22 Aug 2014
Price Change (% chg)

$0.00 (+7.14%)
Prev Close
$0.07
Open
$0.06
Day's High
$0.08
Day's Low
$0.06
Volume
187,175
Avg. Vol
76,299
52-wk High
$0.14
52-wk Low
$0.05

Search Stocks

Latest Key Developments (Source: Significant Developments)

Diagnos Inc announces signing of contract with Ministry of Health Owned Medical Center in United Arab Emirates
Wednesday, 16 Jul 2014 09:30am EDT 

Diagnos Inc:Signing of contract with Al Manama Medical Center for deployment of screening unit and usage of CARA in Unite Arab Emirates, project fully supported by the UAE Ministry of Health.  Full Article

Diagnos completes merger with Warnex Inc
Tuesday, 8 Jul 2014 03:34pm EDT 

Diagnos Inc:Announces the closing of the merger of Warnex Inc. ("WARNEX") with a wholly-owned subsidiary of DIAGNOS initially announced on May 5.Says it will issue 28,323,884 common shares to the shareholders of WARNEX and 1,875,000 stock warrants (the "Diagnos Warrants") to Persistence Capital Partners.  Full Article

Diagnos announces final closing of private placement
Tuesday, 6 May 2014 11:10am EDT 

Diagnos Inc:Closes private placement that was initially announced Feb. 25.In connection with the private placement, 107 units were issued for gross proceeds of $1,070,000.Each Unit consists of $10,000 principal amount, 2 year term, 10pct interest rate, unsecured convertible promissory note.Proceeds to be used for business development, product development and general corporate purposes.  Full Article

DIAGNOS Inc to Merge with Warnex Inc
Monday, 5 May 2014 06:35pm EDT 

DIAGNOS Inc:Says that it has signed a binding letter of agreement with Warnex Inc.Pursuant to which WARNEX will merge with a wholly owned subsidiary of DIAGNOS.Upon the closing of the Transaction, shareholders of WARNEX will receive one common share of DIAGNOS for each common share of WARNEX held.For the purposes of the Transaction, each of the DIAGNOS common shares and the WARNEX common shares have been attributed a value of $0.08 per share.Each shareholder of WARNEX and of DIAGNOS will, upon the closing of the Transaction, also be entitled to receive an additional half-warrant for each WARNEX common share or DIAGNOS common share held.Each whole warrant will be exercisable into one common share of DIAGNOS at an exercise price of $0.10 per share for a period of twelve months following the closing of the Transaction.The current holders of WARNEX warrants will receive one warrant of DIAGNOS for each warrant of WARNEX held.  Full Article

DIAGNOS Inc announces closing of first tranche of private placement
Tuesday, 1 Apr 2014 10:00am EDT 

DIAGNOS Inc:Closes first tranche, consisting of 77 units for gross proceeds of $770,000, of non-brokered private placement consisting of up to 125 units.For gross proceeds of up to $1,250,000 previously announced on Feb. 25.Proceeds of private placement will be used for business development, product development and general corporate purposes.  Full Article

Diagnos inc announces private placement of common share
Tuesday, 25 Feb 2014 09:57am EST 

Diagnos inc:Intention of undertaking a non-brokered private placement consisting of up to 125 units.for gross proceeds of up to $1,250,000.Each unit will consist $10,000 principal amount, 2 year term, 10 pct interest rate.Each unit will consist 50,000 warrants entitling the holder to purchase one common share per warrant, at a price of $0.095 per Share for a period of two years from the date of issuance.Proceeds of the private placement will be used for business development, product development and general corporate purposes.  Full Article

Diagnos Inc announces three year contract with first U.S. based primary care network, Chaparral Medical Group in California
Wednesday, 12 Feb 2014 10:00am EST 

Diagnos Inc:Signs a Contract with California-based Chaparral Medical Group for the deployment and usage of CARA, for diabetic retinopathy screening platform in that state.  Full Article

Diagnos Inc's Diagnos Healthcare (India) Pvt. Ltd signs letter of intent with Aditya Jyot
Monday, 13 Jan 2014 12:00pm EST 

Diagnos Inc:Says Diagnos Healthcare (India) Pvt. Ltd, a subsidiary of the company, signs a Letter of Intent to conclude a Channel Agreement with Aditya Jyot Eye Hospital.Says under the terms of the LOI, DIAGNOS India will provide its CARA screening services to its client initially in Maharashtra followed by national expansion to areas where Aditya Jyot is active.Says DIAGNOS India plans to deploy and operate both Mobile and Managed screening services on behalf of the client and screen up to 30,000 patients annually.Says a formal channel partnership is to be concluded within 90 days.  Full Article

Diagnos Inc announces signing of contract with multinational pharmaceutical organization
Tuesday, 17 Dec 2013 09:30am EST 

Diagnos Inc:Signs on Dec 3, of a 3 year agreement between its Indian Subsidiary, DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED (DIAGNOS India) and a multinational pharmaceutical organization for the deployment of CARA in India.  Full Article

Diagnos Inc Announces the Creation of Indian Subsidiary and the Opening of an Office in India
Wednesday, 18 Sep 2013 09:30am EDT 

DIAGNOS Inc announced the Creation of Indian Subsidiary and the Opening of an Office in Mumbai, India, to support and coordinate deployment and usage of CARA in India. To execute on the LOI signed with a global pharmaceutical company in India, announced on September 4th 2013, Diagnos has created a local subsidiary: Diagnos Healthcare (india) Private Limited. The subsidiary is incorporated in Mumbai, Maharashtra, India, under the Indian Companies Act, as a private limited company approved by Anuradha Bhaskar Athavale, Deputy Registrar of Companies.  Full Article

Search Stocks